Phase I, multi-center, open-label, dose-escalation study of pasireotide LAR (PAS) in patients with advanced neuroendocrine tumors (NET)

Autor:	Madan G. Kundu, Jennifer A. Chan, Edward M. Wolin, Mike Hu, Jonathan R. Strosberg, Sue-zette Valera, Christelle Darstein, James C. Yao, Alain C. Mita, Peter Unge
Rok vydání:	2016
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Neuroendocrine tumors medicine.disease Pasireotide chemistry.chemical_compound chemistry Internal medicine Maximum tolerated dose medicine Dose escalation In patient Open label business Somatostatin analog neoplasms
Zdroj:	Journal of Clinical Oncology. 34:4095-4095
ISSN:	1527-7755 0732-183X
Popis:	4095Background: Pasireotide, a novel somatostatin analog, has been previously investigated but the maximum tolerated dose (MTD) has not been determined in pts with advanced NET. We report results o...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0621b0507a718c7b507feddfefd3240f https://doi.org/10.1200/jco.2016.34.15_suppl.4095 Zobrazit plný text záznamu